Xenon Pharmaceuticals Inc (XENE) — Net Asset Quality Index
Xenon Pharmaceuticals Inc (XENE) has a Net Asset Quality Index of 59.3% as of December 2025. This metric measures the proportion of total assets financed by shareholders' equity — total assets of $981.67 Million minus total liabilities of $399.91 Million yields net assets of $581.76 Million. A higher index indicates a stronger, lower-leverage balance sheet. See XENE defensive asset coverage days to measure how many days the company can operate on defensive assets alone.
Quality Index
Net Assets
Total Assets
Total Liabilities
Xenon Pharmaceuticals Inc Net Asset Quality Index Over Time (2012–2025)
This chart shows how Xenon Pharmaceuticals Inc's Net Asset Quality Index has evolved across 14 annual periods from 2012 to 2025. As of December 2025, the index stands at 59.3%, representing net assets of $581.76 Million against total assets of $981.67 Million USD. Explore cash efficiency ratio of Xenon Pharmaceuticals Inc to assess how effectively this company generates cash.
Annual Net Asset Quality Index for Xenon Pharmaceuticals Inc (2012–2025)
The table below presents the year-by-year Net Asset Quality Index for Xenon Pharmaceuticals Inc from 2012 to 2025, covering 14 annual filings. Each row shows total assets, total liabilities, net assets, the quality index percentage, and the change in percentage points compared to the prior year. For market capitalisation and the full company profile, see market value of Xenon Pharmaceuticals Inc.
| Year | Quality Index | Net Assets (USD) | Total Assets | Total Liabilities | Change (pp) |
|---|---|---|---|---|---|
| 2025 | 59.3% | $581.76 Million | $981.67 Million | $399.91 Million | ▼ -35.3 pp |
| 2024 | 94.6% | $754.90 Million | $798.14 Million | $43.24 Million | ▼ -1.6 pp |
| 2023 | 96.2% | $927.92 Million | $964.80 Million | $36.88 Million | ▲ +0.5 pp |
| 2022 | 95.7% | $721.50 Million | $754.15 Million | $32.65 Million | ▼ -0.5 pp |
| 2021 | 96.2% | $550.03 Million | $572.01 Million | $21.97 Million | ▲ +5.6 pp |
| 2020 | 90.6% | $171.35 Million | $189.19 Million | $17.83 Million | ▲ +28.3 pp |
| 2019 | 62.3% | $91.98 Million | $147.70 Million | $55.72 Million | ▼ -22.1 pp |
| 2018 | 84.4% | $103.30 Million | $122.43 Million | $19.13 Million | ▲ +6.5 pp |
| 2017 | 77.9% | $35.93 Million | $46.12 Million | $10.19 Million | ▼ -16.8 pp |
| 2016 | 94.7% | $63.90 Million | $67.49 Million | $3.59 Million | ▼ -0.8 pp |
| 2015 | 95.4% | $61.03 Million | $63.95 Million | $2.92 Million | ▲ +12.2 pp |
| 2014 | 83.3% | $72.78 Million | $87.42 Million | $14.64 Million | ▲ +39.0 pp |
| 2013 | 44.3% | $24.12 Million | $54.49 Million | $30.37 Million | ▲ +24.3 pp |
| 2012 | 19.9% | $12.62 Million | $63.30 Million | $50.68 Million | — |